Latest News about Phase 1 Trial
Recent news which mentions Phase 1 Trial
ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation
December 13, 2021
Tickers
ALXO
From Benzinga
Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation
December 13, 2021
Tickers
VIRX
From Benzinga
Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet
December 13, 2021
Tickers
HARP
From Benzinga
JNJ's Janssen Posts Two Years Survival Data On BCMA Cell Therapy In Multiple Myeloma
December 13, 2021
From Benzinga
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
December 13, 2021
From Benzinga
Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program
December 13, 2021
Tickers
BLUE
From Benzinga
Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients
December 10, 2021
From Benzinga
From Benzinga
From Benzinga
Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise
December 09, 2021
Tickers
FREQ
From Benzinga
Ideaya Reports New Data From Combo Therapy Regime In Pretreated Eye Cancer Patients
December 07, 2021
Tickers
IDYA
From Benzinga
Prometheus Biosciences Posts Phase 1 Data On Lead Therapeutic Candidate
December 07, 2021
Tickers
RXDX
From Benzinga
Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor
December 07, 2021
Tickers
IVA
From Benzinga
Adagene's Posts Early Safety, Efficacy Data From Cold Tumors Trial
December 07, 2021
Tickers
ADAG
From Benzinga
Bellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer Studies
December 06, 2021
Tickers
BLCM
From Benzinga
Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients
December 06, 2021
From Benzinga
Adicet Stock Rallies After Early Responses For Off-The-Shelf Drug In B-cell Non-Hodgkin's Lymphoma
December 06, 2021
Tickers
ACET
From Benzinga
Fulcrum Therapeutics Shares Additional Data From Phase 1 Trial Of Sickle Cell Disease Treatment
December 06, 2021
Tickers
FULC
From Benzinga
Molecular Partners' Ensovibep Shows Early Safety Profile In COVID-19
December 06, 2021
Tickers
MOLN
From Benzinga
SQZ Biotechnologies' Cell Therapy Shows Favorable Safety Profile In HPV+ Solid Tumors
December 02, 2021
Tickers
SQZ
From Benzinga
Inhibrx Precision Cancer Antibody Receives FDA Orphan Drug Tag For Rare Bone Cancer
December 02, 2021
Tickers
INBX
From Benzinga
Read Why Is Roth Capital Bullish On This Cancer-Focused Stock
December 01, 2021
Tickers
MBRX
From Benzinga
Arbutus' Hepatitis B Candidate Shows Encouraging Antiviral Activity
December 01, 2021
From Benzinga
Mereo BioPharma's Etigilimab/Opdivo Combo Achieves One Complete Response In Cervical Cancer
November 30, 2021
From Benzinga
After Denying Data Leak, Olema Shares First Data For Lead Program In Breast Cancer Patients
November 30, 2021
Tickers
OLMA
From Benzinga
EXCLUSIVE: Hoth Therapeutics Starts Dosing In Second Cohort Of Atopic Dermatitis Trial With BioLexa
November 30, 2021
Tickers
HOTH
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free
Information
Copyright 2024. BUSINESS INSURANCE HOLDINGS
